SKAN Group AGFRA:7VG +2.61%62 EPS without NRI is €0.77 as of Dec. 2025. GuruFocus rates FRA:7VG with a GF Score™ of 62/100 and a GF Value™ of €90.91 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 662 Medical Devices & Instruments companies, SKAN Group AG ranks worse than 67.98% on this metric.
SKAN Group AG's earnings per share without non-recurring items for the
six
months ended in Dec. 2025 was €1.20.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was €0.77.
During the past 12 months, SKAN Group AG's average earnings per share (NRI) Growth Rate was -58.40% per year.
During the past 3 years, the average earnings per share (NRI) Growth Rate was -5.00% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 28.50% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for SKAN Group AG's EPS without NRI or its related term are showing as below:
FRA:7VG'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -5 Med: 27.9 Max: 78.1
Current: -5
During the past 6 years, SKAN Group AG's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 78.10% per year. The lowest was -5.00% per year. And the median was 27.90% per year.
FRA:7VG's 3-Year EPS without NRI Growth Rate is ranked worse than 67.98% of 662
companies
in the Medical Devices & Instruments industry
Industry Median: 8.15
vs FRA:7VG: -5.00
SKAN Group AG's EPS (Diluted) for the
six
months ended in Dec. 2025 was €1.20.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.77.
SKAN Group AG's EPS (Basic) for the
six
months ended in Dec. 2025 was €1.20.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.77.
SKAN Group AG (FRA:7VG) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
SKAN Group AG EPS without NRI Related Terms
SKAN Group AG EPS without NRI Historical Data
* Premium members only.
The historical data trend for SKAN Group AG's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7VG vs ISRG, BDX, MDLN: EPS without NRI Comparison
For the Medical Instruments & Supplies subindustry, SKAN Group AG's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SKAN Group AG PE Ratio without NRI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SKAN Group AG's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where SKAN Group AG's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.77
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SKAN Group AG (FRA:7VG) has a EPS without NRI of €0.77 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on SKAN Group AG and its competitors. According to the industry distribution chart, SKAN Group AG ranks #450 out of 662 companies in the Medical Devices & Instruments industry, placing it in the top 68%.
Is SKAN Group AG's EPS without NRI too high?
SKAN Group AG's current EPS without NRI is €0.77. Based on the distribution chart, SKAN Group AG ranks #450 out of 662 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, SKAN Group AG has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SKAN Group AG's EPS without NRI compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, SKAN Group AG ranks #450 out of 662 companies for EPS without NRI. This places SKAN Group AG in the lower half of its industry. The industry median EPS without NRI is 8.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.15, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on SKAN Group AG and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SKAN Group AG's current EPS without NRI is €0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SKAN Group AG stock overvalued right now?
Based on GuruFocus' analysis, SKAN Group AG (FRA:7VG) is currently considered Significantly Undervalued. The stock's GF Value™ is €90.91, compared to a current price of €59.00 — trading 35.1% below its estimated fair value. The current EPS without NRI is €0.77. SKAN Group AG's overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For SKAN Group AG (FRA:7VG), the current EPS without NRI is €0.77 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SKAN Group AG (FRA:7VG) Overvalued in 2026?
Based on GuruFocus' analysis, SKAN Group AG stock appears to be undervalued.
The current stock price of €59.00 is trading 35.1% below its estimated GF Value™ of €90.91.
GuruFocus considers SKAN Group AG to be Significantly Undervalued.
Key valuation signals for FRA:7VG:
EPS without NRI: €0.77
GF Value™: €90.91 vs. price of €59.00 (35.1% below fair value)
No single metric tells the full story. See the FRA:7VG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SKAN Group AG is a market and technological company for isolators, cleanroom devices, and decontamination processes for the aseptic production of biopharmaceutical substances. The company offers its customers process support, services, and consumables. Its products include biological indicators, isolators, Laboratory/cleanroom equipment, laminar flow, safety workbenches, transfer systems, and others. The Firm has three operating segments: Equipment & solutions, Services & Consumables, and Other. The company generates the majority of its revenue from the Equipment & solutions segment. Geographically, the company derives revenue from Asia, Europe, Americas, and Other regions.
62GF Score
Get the complete analysis for FRA:7VG
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7VG has been successfully added to your 
